Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Cancer Solution with a Leading Digital Pathology Platform
SEOUL, South Korea, Nov. 15, 2022 /PRNewswire-PRWeb/ -- Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the latest AI-powered prostate cancer solution.
- Deep Bio's deep learning-based CE-IVDD prostate cancer diagnosis support software, DeepDx Prostate, empowers pathologists by identifying cancerous areas and grading their severity providing a Gleason scoring.
- With its extensive AI-based image analysis solutions for multiple cancer types, Visiopharm's platform is contributing to the global adoption of digital pathology and AI.
- The two companies plan to add additional AI cancer pathology solutions over time for prostate and breast, among others.
- Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology.